Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.

Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.

<h4>Purpose</h4> <p>We have identified human medicinal products for which animal data were used as evidence for withdrawal, determined whether the adverse reactions were reported in humans, established whether confirmatory human studies were conducted, and explored the withdrawal...

Полное описание

Библиографические подробности
Главные авторы:	Onakpoya, I, Heneghan, C, Aronson, J
Формат:	Journal article
Язык:	English
Опубликовано:	Wiley 2017

Схожие документы

Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
по: Onakpoya, I, и др.
Опубликовано: (2016)

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
по: Onakpoya, I, и др.
Опубликовано: (2016)

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
по: Onakpoya, IJ, и др.
Опубликовано: (2016)

Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
по: Onakpoya, I, и др.
Опубликовано: (2017)

Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
по: Igho J. Onakpoya, и др.
Опубликовано: (2019-03-01)

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
по: Onakpoya, I
Опубликовано: (2017)

Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
по: Onakpoya, I, и др.
Опубликовано: (2017)

The Adverse Drug Reactions Registered During the Postmarketing Period
по: E. V. Shubnikova, и др.
Опубликовано: (2019-03-01)

Rotavirus Vaccine Withdrawal in the United States: The Role of Postmarketing Surveillance
по: Gilles Delage
Опубликовано: (2000-01-01)

Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
по: Onakpoya, I, и др.
Опубликовано: (2018)

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
по: Colleen M. Kingsbury, и др.
Опубликовано: (2024-09-01)

Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
по: Daniele Sartori, и др.
Опубликовано: (2020-08-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
по: Wei Mao, и др.
Опубликовано: (2025-01-01)

Postmarket sequential database surveillance of medical products
по: Maro, Judith C
Опубликовано: (2013)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
по: Yamin Shu, и др.
Опубликовано: (2023-05-01)

Redefining rapid reviews: a flexible framework for restricted systematic reviews
по: Plüddemann, A, и др.
Опубликовано: (2018)

Postmarket Surveillance of Neuroendovascular Devices
по: Marie K. Luff, и др.
Опубликовано: (2024-03-01)

Postmarket Drug Surveillance Without Trial Costs: Discovery of Adverse Drug Reactions Through Large-Scale Analysis of Web Search Queries
по: Yom-Tov, Elad, и др.
Опубликовано: (2013-06-01)

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance
по: Jinyi Yuan, и др.
Опубликовано: (2022-12-01)

Naltrexone‐bupropion (Mysimba®) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
по: Onakpoya, IJ, и др.
Опубликовано: (2020)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
по: John T. Sullivan
Опубликовано: (2022-04-01)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
по: Aronson, J
Опубликовано: (2008)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
по: Kevin Wing, и др.
Опубликовано: (2019-10-01)

An agenda for research on adverse drug reactions.
по: Aronson, J
Опубликовано: (2007)

Adverse drug reactions--no farewell to harms.
по: Aronson, J
Опубликовано: (2007)

Pharmacogenetics and adverse drug reactions
по: Ferner, R, и др.
Опубликовано: (2010)

Clinical efficacy and safety of alemtuzumab in postmarketing practice
по: N. V. Khachanova
Опубликовано: (2019-06-01)

Withdrawn medicines included in the essential medicines lists of 136 countries.
по: Onella Charles, и др.
Опубликовано: (2019-01-01)

Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance
по: Goeun Park, и др.
Опубликовано: (2020-08-01)

Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014–19
по: Pasquale Stefanizzi, и др.
Опубликовано: (2022-01-01)

Serum trough level as a postmarketing quality measure of generic vancomycin products
по: Ya-Wen Tsai, и др.
Опубликовано: (2020-04-01)

Postmarketing Surveillance: Review of Open Sources of Drug Safety Data
по: E. V. Shubnikova
Опубликовано: (2024-10-01)

Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: A systematic review and meta-analysis of randomised clinical trials.
по: Onakpoya, I, и др.
Опубликовано: (2014)

The need for randomization in animal trials: an overview of systematic reviews
по: Hirst, J, и др.
Опубликовано: (2014)

Reduced salt intake for heart failure: A systematic review
по: Mahtani, K, и др.
Опубликовано: (2018)

Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process.
по: Heneghan, C, и др.
Опубликовано: (2017)

Orphan Therapies: Making Best Use of Postmarket Data
по: Li, Lingling, и др.
Опубликовано: (2016)

Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis
по: Huqun Li, и др.
Опубликовано: (2025-01-01)

Pharmacoepidemiology – Assessing the Risks and Benefits of Drugs in the Postmarketing Phase
по: Christoph R. Meier
Опубликовано: (2006-02-01)

Sleep-walking with zolpidem: Need for continued postmarketing surveillance
по: Ajitha Sharma, и др.
Опубликовано: (2015-01-01)